Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma.

Abstract:

:Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Areas Covered: We review CSCC and the studies leading to cemiplimab's approval, including common side effects and safety issues experienced during the clinical trials. Expert Opinion: Immunotherapy, specifically checkpoint inhibitors, represents an increasingly utilized class of medications that is proving to be an effective treatment option for those with certain cancers. Over time, immunotherapy is likely to be the standard of care for immune-sensitive tumors. There are many challenges that the field faces, including the identification of reliable biomarkers to better predict response, decreasing toxicity, and the potential treatment of organ transplant patients.

authors

Ahmed SR,Petersen E,Patel R,Migden MR

doi

10.1080/17512433.2019.1665026

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

947-951

issue

10

eissn

1751-2433

issn

1751-2441

journal_volume

12

pub_type

杂志文章,评审
  • G-quadruplex interacting small molecules and drugs: from bench toward bedside.

    abstract::G-quadruplexes are non-Watson-Crick four-stranded nucleic acid structures. Recent evidence points toward their existence in vivo and their implication in various biological processes. Over the past two decades, small molecules have been developed to specifically and selectively target these structures in order to diss...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.945909

    authors: Müller S,Rodriguez R

    更新日期:2014-09-01 00:00:00

  • The role of the placenta in drug transport and fetal drug exposure.

    abstract:INTRODUCTION:It was assumed for decades that the human placenta serves as a barrier, protecting the fetus from exposure to xenobiotics circulating in the mother. The thalidomide disaster completely reversed this concept. The study of the human placenta is therefore critical to understanding the mechanisms by which xeno...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1425615

    authors: Koren G,Ornoy A

    更新日期:2018-04-01 00:00:00

  • Can a fixed-ratio combination of insulin degludec and liraglutide help Type 2 diabetes patients to optimize glycemic control across the day?

    abstract::'IDegLira' combines insulin degludec (IDeg) with the glucagon-like peptide-1 analog liraglutide (Lira) at a ratio of 1 unit IDeg to 0.036 mg Lira. The two components have complementary therapeutic actions for the treatment of Type 2 diabetes. Studies have shown that combinations of basal insulin with glucagon-like pep...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2015.1017562

    authors: Simpson R,King A

    更新日期:2015-03-01 00:00:00

  • Methods for optimizing statistical analyses in pharmacogenomics research.

    abstract::Pharmacogenomics is a rapidly developing sector of human genetics research with arguably the highest potential for immediate benefit. There is a considerable body of evidence demonstrating that variability in drug-treatment response can be explained in part by genetic variation. Subsequently, much research has ensued ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/ecp.09.32

    authors: Turner SD,Crawford DC,Ritchie MD

    更新日期:2009-09-01 00:00:00

  • The genetics of vascular incidents associated with second-generation antipsychotic administration.

    abstract::Second-generation antipsychotics (SGA) have been associated with risk of stroke in elderly patients, but the molecular and genetic background under this association has been poorly investigated. The aim of the present study was to prioritize a list of genes with an SGA altered expression in order to characterize the g...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.865515

    authors: Cocchi E,Drago A,de Ronchi D,Serretti A

    更新日期:2014-01-01 00:00:00

  • Effects of red wine on established markers of arterial structure and function in human studies: current knowledge and future research directions.

    abstract::Evidence from observational studies suggests that mild-to-moderate consumption of red wine is associated with reduced cardiovascular morbidity and mortality. Various individual chemical components of red wine also show salutary effects on vascular homeostasis, that is, enhanced endothelial function and arterial disten...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2013.841077

    authors: Mangoni AA,Stockley CS,Woodman RJ

    更新日期:2013-11-01 00:00:00

  • Novel Therapies for Thyroid Autoimmune Diseases.

    abstract::C-X-C chemokine receptor (CXCR)3 and its interferon(IFN)γ-dependent chemokines (CXCL10, CXCL9, CXCL11) are implicated in the immune-pathogenesis of autoimmune thyroiditis (AT), Graves disease (GD) and Graves Ophthalmopathy (GO). In tissue, recruited Th1 lymphocytes produce IFNγ, enhancing the tissue secretion of IFNγ-...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1157468

    authors: Fallahi P,Ferrari SM,Elia G,Nasini F,Colaci M,Giuggioli D,Vita R,Benvenga S,Ferri C,Antonelli A

    更新日期:2016-06-01 00:00:00

  • A clinical perspective on escalating or de-escalating adjuvant therapy in HER2+ breast cancer.

    abstract::Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2019.1552134

    authors: Esposito A,Viale G,Criscitiello C,Curigliano G

    更新日期:2019-01-01 00:00:00

  • Polypharmacy among adult and older adult users of primary care services delivered through the Unified Health System in Minas Gerais, Brazil.

    abstract:OBJECTIVES:To estimate the prevalence of polypharmacy (≥5 drugs) among adults and to analyze related factors. METHODS:Cross-sectional study with 1,159 interviewees distributed across 104 cities and 253 primary healthcare services delivered through the Brazilian Unified Health System. Polypharmacy-related factors were ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1080/17512433.2020.1836958

    authors: Moreira T,Alvares-Teodoro J,Barbosa MM,Do Nascimento RCRM,Guerra Júnior AA,Acurcio FA

    更新日期:2020-12-01 00:00:00

  • Crofelemer for the symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy.

    abstract::Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.1082424

    authors: Castro JG,Chin-Beckford N

    更新日期:2015-01-01 00:00:00

  • Dapsone-associated fixed drug eruption.

    abstract:INTRODUCTION:Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature se...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1322508

    authors: Garcia D,Cohen PR

    更新日期:2017-07-01 00:00:00

  • Sugammadex: a novel selective relaxant binding agent.

    abstract::Sugammadex, a modified γ-cyclodextrin, is the first selective relaxant binding agent. Sugammadex forms very tight complexes in a 1:1 ratio with steroidal neuromuscular blocking agents (rocuronium > vecuronium > pancuronium). This guest-host complex, which exists in equilibrium, is stable because of its very high assoc...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2.1.37

    authors: Naguib M,Brull SJ

    更新日期:2009-01-01 00:00:00

  • Amlodipine and celecoxib for treatment of hypertension and osteoarthritis pain.

    abstract:INTRODUCTION:Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1540299

    authors: Angeli F,Trapasso M,Signorotti S,Verdecchia P,Reboldi G

    更新日期:2018-11-01 00:00:00

  • Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.

    abstract::Rosacea is a chronic inflammatory dermatologic condition that can often be disfiguring with significant negative impact on patients' quality of life. Sanrosa (brimonidine tartate) is a novel therapeutic agent targeting the facial flushing and erythema of rosacea through its α₂ adrenergic receptor agonist activity. The...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2014.945910

    authors: Tong LX,Moore AY

    更新日期:2014-09-01 00:00:00

  • Secukinumab (AIN-457) for the treatment of Psoriasis.

    abstract::Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1129894

    authors: Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

    更新日期:2016-01-01 00:00:00

  • Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.

    abstract:INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1230495

    authors: Zingler G,Hermann B,Fischer T,Herdegen T

    更新日期:2016-11-01 00:00:00

  • The pathophysiological and pharmacological basis of current drug treatment of migraine headache.

    abstract::Migraine is a common neurological syndrome that affects approximately 10-20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the pathogenesis of migraine and thus 5-HT1-receptor agonists are the principal drugs for acute migraine therapy. There are three classes ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.13.14

    authors: Reddy DS

    更新日期:2013-05-01 00:00:00

  • Clinical pharmacology of linezolid: an oxazolidinone antimicrobial agent.

    abstract::The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections cause...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.1.4.479

    authors: Tan TQ,Yogev R

    更新日期:2008-07-01 00:00:00

  • Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity.

    abstract::Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1100072

    authors: Ali KF,Shukla AP,Aronne LJ

    更新日期:2016-01-01 00:00:00

  • Seek and destroy: improving PK/PD profiles of anticancer agents with nanoparticles.

    abstract:INTRODUCTION:The Pharmacokinetics/pharmacodynamics (PK/PD) relationships with cytotoxics are usually based on a steepening concentration-effect relationship; the greater the drug amount, the greater the effect. The Maximum Tolerated Dose paradigm, finding the balance between efficacy, while keeping toxicities at their ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1477586

    authors: Rodallec A,Fanciullino R,Lacarelle B,Ciccolini J

    更新日期:2018-06-01 00:00:00

  • Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.

    abstract:INTRODUCTION:A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of a...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2017.1341308

    authors: Nelson AL

    更新日期:2017-08-01 00:00:00

  • Pharmacological resources, diagnostic approach and coordination of care in joint hypermobility-related disorders.

    abstract:INTRODUCTION:Joint hypermobility (JH) is the hallmark of many hereditary soft connective tissue disorders, including Ehlers-Danlos syndromes and related disorders, disorders of the TGFβ-pathway, lateral meningocele syndrome, arterial tortuosity syndrome, and cutis laxa syndromes. Contemporary practice separates individ...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2018.1497973

    authors: Baban A,Castori M

    更新日期:2018-07-01 00:00:00

  • Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.

    abstract:INTRODUCTION:WHO recommends tenofovir, efavirenz, and lamivudine or emtricitabine for first-line antiretroviral therapy (ART) in adults, which replaced more toxic regimens using stavudine, zidovudine or nevirapine. Areas covered: We searched Pubmed to identify observational studies and randomized controlled trials repo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1080/17512433.2016.1221760

    authors: Mouton JP,Cohen K,Maartens G

    更新日期:2016-11-01 00:00:00

  • Hydrogen sulfide in the endocrine and reproductive systems.

    abstract::Hydrogen sulfide (H(2)S) is now considered a member of a group of signaling molecules termed 'gasotransmitters'. H(2)S has been shown to be generated in the endocrine and reproductive organs and elicits various actions. H(2)S modulates insulin secretion in pancreatic islets. Adipose tissues have the ability to produce...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.10.125

    authors: Zhu XY,Gu H,Ni X

    更新日期:2011-01-01 00:00:00

  • Statin intolerance: more questions than answers.

    abstract::The dramatic effectiveness of statins in improving the course of atherosclerotic cardiovascular disease tends to overshadow questions of statin intolerance. Thus after more than 25 years of clinical statin use, intolerance remains a poorly understood, frustrating issue for patients and providers. It has been extraordi...

    journal_title:Expert review of clinical pharmacology

    pub_type: 社论

    doi:10.1586/17512433.2014.857601

    authors: Guyton JR,Campbell KB,Lakey WC

    更新日期:2014-01-01 00:00:00

  • Combating inappropriate use of medicines.

    abstract::Globally, it is possible that less than half of all patients are treated in compliance with guidelines and more than half of all patients fail to take their medicines as prescribed or dispensed. Such inappropriate use is wasteful of resources and causes patient harm in terms of lack of satisfactory outcome, serious ad...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/ecp.11.14

    authors: Holloway KA

    更新日期:2011-05-01 00:00:00

  • Lipid-based delivery of CpG oligodeoxynucleotides for cancer immunotherapy.

    abstract::The anti-tumor activity of CpG-containing oligodeoxynucleotides (ODNs) has been well established in numerous animal models and confirmed in a number of early clinical trials. While the use of chemical modifications has effectively reduced the sensitivity of ODNs to nuclease degradation and a number of human trials hav...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章

    doi:10.1586/17512433.2.2.181

    authors: Wilson KD,Tam YK

    更新日期:2009-03-01 00:00:00

  • Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin: rationale and evidences.

    abstract::Sodium-glucose co-transporter-2 inhibitors (SGLT-2I) are recently approved class of anti-hyperglycaemic agents for the treatment of type 2 diabetes mellitus (T2DM). SGLT-2I inhibits renal glucose reabsorption, thereby ensuing urinary glucose excretion in a dose-dependent manner. This caloric loss and osmotic diuresis,...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2016.1131121

    authors: Singh AK,Singh R

    更新日期:2016-01-01 00:00:00

  • Novel disease-modifying therapeutics for the treatment of Alzheimer's disease.

    abstract::Alzheimer's disease is the most common cause of dementia and is becoming a global health concern. Despite a well-established understanding of the molecular mechanism involved in its pathogenesis, and millions of dollars of investment in drug discovery and clinical trials, no single molecule has yet been approved for i...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2013.811237

    authors: Léger GC,Massoud F

    更新日期:2013-07-01 00:00:00

  • Antiepileptic drugs influences on body weight in people with epilepsy.

    abstract::Data from clinical trials, retrospective and cross-sectional studies have quantified the metabolic changes associated with long-term use of antiepileptic drugs (AEDs). AEDs can be associated with weight gain or weight loss, although most are weight neutral. Weight gain is not only a cosmetic problem but also a risk fo...

    journal_title:Expert review of clinical pharmacology

    pub_type: 杂志文章,评审

    doi:10.1586/17512433.2015.991716

    authors: Hamed SA

    更新日期:2015-01-01 00:00:00